Publications by authors named "Debby Long"

Claim this Profile
P
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Debby Long

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-((2,4)-4-Ethoxy-1-((5-methoxy-7-methyl-1-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
Nello Mainolfi, Takeru Ehara, Rajeshri G Karki, Karen Anderson, Aengus Mac Sweeney, Debby Long

J Med Chem· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Rajeshri G Karki, James Powers, Nello Mainolfi, Karen Anderson, David B Belanger, Debby Long

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
Christopher M Adams, Karen Anderson, Gerald Artman, Jean-Claude Bizec, Rosemarie Cepeda, Debby Long

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit.
Kerri J Grove, Viral Kansara, Melissa Prentiss, Debby Long, Muneto Mogi

SLAS Discov· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting protein drugs for the treatment of ocular diseases.
Joy G Ghosh, Andrew A Nguyen, Chad E Bigelow, Stephen Poor, Yubin Qiu, Debby Long

Nat Commun· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.
Erik L Meredith, Nello Mainolfi, Stephen Poor, Yubin Qiu, Karl Miranda, Debby Long

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.
Nello Mainolfi, James Powers, Jakal Amin, Debby Long, Wendy Lee

J Med Chem· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.
Jeremy M Sivak, Allison C Ostriker, Amber Woolfenden, John Demirs, Rosemarie Cepeda, Debby Long

J Biol Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis